Metabolic Diseases: Cellular and Molecular Mechanisms: A Point of View

POINT OF VIEW
Gundu H. R. Rao

For citation: Rao GHR. Metabolic Diseases: Cellular and Molecular Mechanisms: A Point of View. International Journal of Biomedicine. 2026;16(1):130-144. doi:10.21103/Article16(2)_PV
 
Originally published June 5, 2026

Abstract: 

The Developmental Origins of Health and Disease (DOHaD) framework highlights that unfavorable conditions during fetal development can trigger persistent biological changes, increasing the risk of metabolic disorders in adulthood. While clinical manifestations often appear only later in life, fetal programming produces subtle but permanent structural, functional, and epigenetic modifications in key metabolic organs—including the pancreas, liver, and skeletal muscle. These early alterations weaken physiological resilience and predispose tissues to dysfunction when exposed to postnatal challenges such as poor diet, sedentary behavior, chronic stress, or environmental toxins. Initially, compensatory mechanisms may mask these vulnerabilities, but with aging and cumulative metabolic stress, these reserves decline, culminating in overt conditions such as hypertension, obesity, type 2 diabetes, and vascular disease. Cellular and molecular mechanisms—including epigenetic remodeling, disrupted signaling pathways, mitochondrial impairment, and chronic low-grade inflammation—serve as mediators linking early-life insults to long-term metabolic dysregulation. Because individuals with normal birth weight also develop these disorders with advancing age, it is plausible that such disease clusters have an age-related component. Downstream consequences of metabolic dysfunction—such as oxidative stress, impaired vascular tone, endothelial dysfunction, dysregulated glucose and lipid metabolism, arterial narrowing, and activation of platelet and coagulation pathways—further drive the progression of metabolic risk. By dissecting these mechanisms, it becomes possible to identify early biomarkers and design targeted interventions that halt disease progression before irreversible damage sets in. Thus, integrating developmental biology with molecular medicine offers a powerful opportunity to prevent and treat metabolic disorders rooted in early life. However, contemporary medical practice remains largely disease-focused, emphasizing management of established risk factors. A more forward-looking approach must prioritize early detection, preventive strategies, and lifestyle modification, guided by a deep understanding of the cellular and molecular foundations of metabolic vulnerability. The Developmental Origins of Health and Disease (DOHaD) framework highlights that unfavorable conditions during fetal development can trigger persistent biological changes, increasing the risk of metabolic disorders in adulthood. While clinical manifestations often appear only later in life, fetal programming produces subtle but permanent structural, functional, and epigenetic modifications in key metabolic organs—including the pancreas, liver, and skeletal muscle. These early alterations weaken physiological resilience and predispose tissues to dysfunction when exposed to postnatal challenges such as poor diet, sedentary behavior, chronic stress, or environmental toxins. Initially, compensatory mechanisms may mask these vulnerabilities, but with aging and cumulative metabolic stress, these reserves decline, culminating in overt conditions such as hypertension, obesity, type 2 diabetes, and vascular disease. Cellular and molecular mechanisms—including epigenetic remodeling, disrupted signaling pathways, mitochondrial impairment, and chronic low-grade inflammation—serve as mediators linking early-life insults to long-term metabolic dysregulation. Because individuals with normal birth weight also develop these disorders with advancing age, it is plausible that such disease clusters have an age-related component. Downstream consequences of metabolic dysfunction—such as oxidative stress, impaired vascular tone, endothelial dysfunction, dysregulated glucose and lipid metabolism, arterial narrowing, and activation of platelet and coagulation pathways—further drive the progression of metabolic risk. By dissecting these mechanisms, it becomes possible to identify early biomarkers and design targeted interventions that halt disease progression before irreversible damage sets in. Thus, integrating developmental biology with molecular medicine offers a powerful opportunity to prevent and treat metabolic disorders rooted in early life. However, contemporary medical practice remains largely disease-focused, emphasizing management of established risk factors. A more forward-looking approach must prioritize early detection, preventive strategies, and lifestyle modification, guided by a deep understanding of the cellular and molecular foundations of metabolic vulnerability.

Keywords: 
oxidative stress • inflammation • vascular dysfunction • hypertension • obesity • diabetes • vascular disease
References: 
  1. Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. Lancet. 1986 May 10;1(8489):1077-81. doi: 10.1016/s0140-6736(86)91340-1. PMID: 2871345.
  2. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet. 1989 Sep 9;2(8663):577-80. doi: 10.1016/s0140-6736(89)90710-1. PMID: 2570282.
  3. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993 Apr 10;341(8850):938-41. doi: 10.1016/0140-6736(93)91224-a. PMID: 8096277.
  4. Barker DJ. The origins of the developmental origins theory. J Intern Med. 2007 May;261(5):412-7. doi: 10.1111/j.1365-2796.2007.01809.x. PMID: 17444880.
  5. Junien C, Nathanielsz P. Report on the IASO Stock Conference 2006: early and lifelong environmental epigenomic programming of metabolic syndrome, obesity and type II diabetes. Obes Rev. 2007 Nov;8(6):487-502. doi: 10.1111/j.1467-789X.2007.00371.x. PMID: 17949354.
  6. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science. 2001 Aug 10;293(5532):1089-93. doi: 10.1126/science.1063443. PMID: 11498579.
  7. Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition. 2004 Jan;20(1):63-8. doi: 10.1016/j.nut.2003.09.011. PMID: 14698016.
  8. Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, Szyf M. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci. 2005 Nov 23;25(47):11045-54. doi: 10.1523/JNEUROSCI.3652-05.2005. PMID: 16306417; PMCID: PMC6725868.
  9. Wadhwa PD, Buss C, Entringer S, Swanson JM. Developmental origins of health and disease: brief history of the approach and current focus on epigenetic mechanisms. Semin Reprod Med. 2009 Sep;27(5):358-68. doi: 10.1055/s-0029-1237424. Epub 2009 Aug 26. PMID: 19711246; PMCID: PMC2862635.
  10. Krishna M, Kumar GM, Veena SR, Krishnaveni GV, Kumaran K, Karat SC, Coakley P, Osmond C, Copeland JR, Chandak G, Bhat D, Varghese M, Prince M, Fall C. Birth size, risk factors across life and cognition in late life: protocol of prospective longitudinal follow-up of the MYNAH (MYsore studies of Natal effects on Ageing and Health) cohort. BMJ Open. 2017 Feb 16;7(2):e012552. doi: 10.1136/bmjopen-2016-012552. PMID: 28209604; PMCID: PMC5318644.
  11. Krishnaveni GV, Veena SR, Hill JC, Karat SC, Fall CH. Cohort profile: Mysore parthenon birth cohort. Int J Epidemiol. 2015 Feb;44(1):28-36. doi: 10.1093/ije/dyu050. Epub 2014 Mar 7. PMID: 24609067; PMCID: PMC4266599.
  12. Krishna M, Kalyanaraman K, Veena SR, Krishanveni GV, Karat SC, Cox V, Coakley P, Nagaraj K, Stein C, Paul B, Prince M, Osmond C, Fall CH. Cohort Profile: The 1934-66 Mysore Birth Records Cohort in South India. Int J Epidemiol. 2015 Dec;44(6):1833-41. doi: 10.1093/ije/dyv176. Epub 2015 Oct 7. PMID: 26445965; PMCID: PMC4690000.
  13. Law CM, de Swiet M, Osmond C, Fayers PM, Barker DJ, Cruddas AM, Fall CH. Initiation of hypertension in utero and its amplification throughout life. BMJ. 1993 Jan 2;306(6869):24-7. doi: 10.1136/bmj.306.6869.24. PMID: 8435572; PMCID: PMC1676382.
  14. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993 Apr 10;341(8850):938-41. doi: 10.1016/0140-6736(93)91224-a. PMID: 8096277.
  15. Barker DJ. Fetal origins of coronary heart disease. BMJ. 1995 Jul 15;311(6998):171-4. doi: 10.1136/bmj.311.6998.171. PMID: 7613432; PMCID: PMC2550226.
  16. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, Ezzati M, Grantham-McGregor S, Katz J, Martorell R, Uauy R; Maternal and Child Nutrition Study Group. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet. 2013 Aug 3;382(9890):427-451. doi: 10.1016/S0140-6736(13)60937-X. Epub 2013 Jun 6. Erratum in: Lancet. 2013. 2013 Aug 3;382(9890):396. PMID: 23746772.
  17. Fall CH, Stein CE, Kumaran K, Cox V, Osmond C, Barker DJ, Hales CN. Size at birth, maternal weight, and type 2 diabetes in South India. Diabet Med. 1998 Mar;15(3):220-7. doi: 10.1002/(SICI)1096-9136(199803)15:3<220::AID-DIA544>3.0.CO;2-O. PMID: 9545123.
  18. Ward AM, Fall CH, Stein CE, Kumaran K, Veena SR, Wood PJ, Syddall HE, Phillips DI. Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol (Oxf). 2003 Apr;58(4):500-5. doi: 10.1046/j.1365-2265.2003.01750.x. PMID: 12641634; PMCID: PMC3405820.
  19. Kumaran K, Fall CHD. Fetal origins of coronary heart disease and hypertension and its relevance to India. Review of evidence from the Mysore studies. Int J Diab. Dev Countries 21:34-41, 2001.
  20. Kuneš J, Hojná S, Mráziková L, Montezano A, Touyz RM, Maletínská L. Obesity, Cardiovascular and Neurodegenerative Diseases: Potential Common Mechanisms. Physiol Res. 2023 Jul 31;72(Suppl 2):S73-S90. doi: 10.33549/physiolres.935109. PMID: 37565414; PMCID: PMC10660578.
  21. Nakamura M, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol. 2020 Jul;598(14):2977-2993. doi: 10.1113/JP276747. Epub 2019 Apr 3. PMID: 30869158.
  22. Giglio RV, Stoian AP, Haluzik M, Pafili K, Patti AM, Rizvi AA, Ciaccio M, Papanas N, Rizzo M. Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochim Biophys Acta Mol Basis Dis. 2021 Aug 1;1867(8):166148. doi: 10.1016/j.bbadis.2021.166148. Epub 2021 Apr 20. PMID: 33892081.
  23. Zhu Z, Cao F, Li X. Epigenetic Programming and Fetal Metabolic Programming. Front Endocrinol (Lausanne). 2019 Dec 3;10:764. doi: 10.3389/fendo.2019.00764. PMID: 31849831; PMCID: PMC6901800.
  24. Barker DJ. In utero programming of chronic disease. Clin Sci (Lond). 1998 Aug;95(2):115-28. PMID: 9680492.
  25. O'Dowd JF, Stocker CJ. Endocrine pancreatic development: impact of obesity and diet. Front Physiol. 2013 Jul 18;4:170. doi: 10.3389/fphys.2013.00170. PMID: 23882220; PMCID: PMC3714448.
  26. Avrahami D, Kaestner KH. Epigenetic regulation of pancreas development and function. Semin Cell Dev Biol. 2012 Aug;23(6):693-700. doi: 10.1016/j.semcdb.2012.06.002. Epub 2012 Jun 21. PMID: 22728076; PMCID: PMC3423529.
  27. Deodati A, Inzaghi E, Cianfarani S. Epigenetics and In Utero Acquired Predisposition to Metabolic Disease. Front Genet. 2020 Jan 29;10:1270. doi: 10.3389/fgene.2019.01270. PMID: 32082357; PMCID: PMC7000755.
  28. Faa G, Fanos V, Manchia M, Van Eyken P, Suri JS, Saba L. The fascinating theory of fetal programming of adult diseases: A review of the fundamentals of the Barker hypothesis. J Public Health Res. 2024 Mar 1;13(1):22799036241226817. doi: 10.1177/22799036241226817. PMID: 38434579; PMCID: PMC10908242.
  29. Lecoutre S, Maqdasy S, Lambert M, Breton C. The Impact of Maternal Obesity on Adipose Progenitor Cells. Biomedicines. 2023 Dec 8;11(12):3252. doi: 10.3390/biomedicines11123252. PMID: 38137473; PMCID: PMC10741630.
  30. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005 Mar;115(3):e290-6. doi: 10.1542/peds.2004-1808. PMID: 15741354.
  31. Al Aboud NM, Tupper C, Jialal I. Genetics, Epigenetic Mechanism. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 30422591.
  32. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, Slagboom PE, Lumey LH. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17046-9. doi: 10.1073/pnas.0806560105. Epub 2008 Oct 27. PMID: 18955703; PMCID: PMC2579375.
  33. Kimura H. Histone modifications for human epigenome analysis. J Hum Genet. 2013 Jul;58(7):439-45. doi: 10.1038/jhg.2013.66. Epub 2013 Jun 6. PMID: 23739122.
  34. Dupont C, Kappeler L, Saget S, Grandjean V, Lévy R. Role of miRNA in the Transmission of Metabolic Diseases Associated With Paternal Diet-Induced Obesity. Front Genet. 2019 Apr 18;10:337. doi: 10.3389/fgene.2019.00337. PMID: 31057600; PMCID: PMC6482346.
  35. Chernausek SD. Update: consequences of abnormal fetal growth. J Clin Endocrinol Metab. 2012 Mar;97(3):689-95. doi: 10.1210/jc.2011-2741. Epub 2012 Jan 11. PMID: 22238390; PMCID: PMC3319209.
  36. Harmancıoğlu B, Kabaran S. Maternal high fat diets: impacts on offspring obesity and epigenetic hypothalamic programming. Front Genet. 2023 May 11;14:1158089. doi: 10.3389/fgene.2023.1158089. PMID: 37252665; PMCID: PMC10211392.
  37. Vaiserman A, Lushchak O. Prenatal Malnutrition-Induced Epigenetic Dysregulation as a Risk Factor for Type 2 Diabetes. Int J Genomics. 2019 Feb 28;2019:3821409. doi: 10.1155/2019/3821409. PMID: 30944826; PMCID: PMC6421750.
  38. Bianco-Miotto T, Craig JM, Gasser YP, van Dijk SJ, Ozanne SE. Epigenetics and DOHaD: from basics to birth and beyond. J Dev Orig Health Dis. 2017 Oct;8(5):513-519. doi: 10.1017/S2040174417000733. Epub 2017 Sep 11. PMID: 28889823.
  39. Barker DJ. The fetal and infant origins of adult disease. BMJ. 1990 Nov 17;301(6761):1111. doi: 10.1136/bmj.301.6761.1111. PMID: 2252919; PMCID: PMC1664286.
  40. Heerwagen MJ, Miller MR, Barbour LA, Friedman JE. Maternal obesity and fetal metabolic programming: a fertile epigenetic soil. Am J Physiol Regul Integr Comp Physiol. 2010 Sep;299(3):R711-22. doi: 10.1152/ajpregu.00310.2010. Epub 2010 Jul 14. PMID: 20631295; PMCID: PMC2944425.
  41. Fall CHD, Kumaran K. Metabolic programming in early life in humans. Philos Trans R Soc Lond B Biol Sci. 2019 Apr 15;374(1770):20180123. doi: 10.1098/rstb.2018.0123. PMID: 30966889; PMCID: PMC6460078.
  42. Kundakovic M, Jaric I. The Epigenetic Link between Prenatal Adverse Environments and Neurodevelopmental Disorders. Genes (Basel). 2017 Mar 18;8(3):104. doi: 10.3390/genes8030104. PMID: 28335457; PMCID: PMC5368708.
  43. Bale TL, Baram TZ, Brown AS, Goldstein JM, Insel TR, McCarthy MM, Nemeroff CB, Reyes TM, Simerly RB, Susser ES, Nestler EJ. Early life programming and neurodevelopmental disorders. Biol Psychiatry. 2010 Aug 15;68(4):314-9. doi: 10.1016/j.biopsych.2010.05.028. PMID: 20674602; PMCID: PMC3168778.
  44. Hill DJ, Hill TG. Maternal diet during pregnancy and adaptive changes in the maternal and fetal pancreas have implications for future metabolic health. Front Endocrinol (Lausanne). 2024 Sep 23;15:1456629. doi: 10.3389/fendo.2024.1456629. PMID: 39377073; PMCID: PMC11456468.
  45. Park JH, Moon JH, Kim HJ, Kong MH, Oh YH. Sedentary Lifestyle: Overview of Updated Evidence of Potential Health Risks. Korean J Fam Med. 2020 Nov;41(6):365-373. doi: 10.4082/kjfm.20.0165. Epub 2020 Nov 19. PMID: 33242381; PMCID: PMC7700832.
  46. Rabasa C, Dickinson SL. Impact of stress on metabolism and energy balance. Curr Opin Behavior Sci. 9:71-77,2016. doi:10.1016/cobeha.2016.01.011.
  47. Lubrano C, Parisi F, Cetin I. Impact of Maternal Environment and Inflammation on Fetal Neurodevelopment. Antioxidants (Basel). 2024 Apr 11;13(4):453. doi: 10.3390/antiox13040453. PMID: 38671901; PMCID: PMC11047368.
  48. Le Magueresse-Battistoni B, Vidal H, Naville D. Environmental Pollutants and Metabolic Disorders: The Multi-Exposure Scenario of Life. Front Endocrinol (Lausanne). 2018 Oct 2;9:582. doi: 10.3389/fendo.2018.00582. PMID: 30333793; PMCID: PMC6176085.
  49. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med. 2002 Apr;8(2):185-92. doi: 10.1089/107555302317371479. PMID: 12006126.
  50. Le Magueresse-Battistoni B, Vidal H, Naville D. Lifelong consumption of low-dosed food pollutants and metabolic health. J Epidemiol Community Health. 2015 Jun;69(6):512-5. doi: 10.1136/jech-2014-203913. Epub 2014 Dec 3. PMID: 25472636.
  51. Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, Powers AC, Rhodes CJ, Sussel L, Weir GC. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care. 2014 Jun;37(6):1751-8. doi: 10.2337/dc14-0396. Epub 2014 May 8. PMID: 24812433; PMCID: PMC4179518.
  52. Zhang K, Ma Y, Luo Y, Song Y, Xiong G, Ma Y, Sun X, Kan C. Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health. Front Public Health. 2023 Oct 13;11:1253506. doi: 10.3389/fpubh.2023.1253506. PMID: 37900047; PMCID: PMC10603303.
  53. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013 Mar 27;4:37. doi: 10.3389/fendo.2013.00037. PMID: 23542897; PMCID: PMC3608918.
  54. Malhotra N, Malhotra J, Bora NM et al. Fetal origin of adult disease. Donald School J. Ultrasound Obstet. Gynecol.2014;8(2):164-177.
  55. Shenkin SD, Starr JM, Deary IJ. Birth weight and cognitive ability in childhood: a systematic review. Psychol Bull. 2004 Nov;130(6):989-1013. doi: 10.1037/0033-2909.130.6.989. PMID: 15535745.
  56. Shenkin SD, Deary IJ, Starr JM. Birth parameters and cognitive ability in older age: a follow-up study of people born 1921-1926. Gerontology. 2009;55(1):92-8. doi: 10.1159/000163444. Epub 2008 Oct 9. PMID: 18843177.
  57. Gale CR, Walton S, Martyn CN. Foetal and postnatal head growth and risk of cognitive decline in old age. Brain. 2003 Oct;126(Pt 10):2273-8. doi: 10.1093/brain/awg225. Epub 2003 Jun 23. PMID: 12821508.
  58. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol. 2009 Mar;66(3):300-5. doi: 10.1001/archneurol.2009.27. PMID: 19273747; PMCID: PMC2717716.
  59. Miller DB, O'Callaghan JP. Do early-life insults contribute to the late-life development of Parkinson and Alzheimer diseases? Metabolism. 2008 Oct;57 Suppl 2:S44-9. doi: 10.1016/j.metabol.2008.07.011. PMID: 18803966.
  60. Ferrante SC, Nadler EP, Pillai DK, Hubal MJ, Wang Z, Wang JM, Gordish-Dressman H, Koeck E, Sevilla S, Wiles AA, Freishtat RJ. Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease. Pediatr Res. 2015 Mar;77(3):447-54. doi: 10.1038/pr.2014.202. Epub 2014 Dec 17. PMID: 25518011; PMCID: PMC4346410.
  61. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011;1(1):98-110. Epub 2010 Oct 22. PMID: 21969178; PMCID: PMC3180104.
  62. Freishtat R. Maternal Adipocyte-derived Exosomes in the Thin-Fat Baby Paradox. Fogarty International Research Grant, National Institutes of Health (NIH), 1R21 HD094127-01. 2018-2020.
  63. Rao GHR. Fetal Origin of Adult Cardiometabolic Diseases: Micronutrient and micro RNA Interventions. EC Endocrinol. Metab Res.2019; 4.1:07-16.
  64. Mensah GA, Fuster V, Murray CJL, Roth GA; Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J Am Coll Cardiol. 2023 Dec 19;82(25):2350-2473. doi: 10.1016/j.jacc.2023.11.007. PMID: 38092509; PMCID: PMC7615984.
  65. Huang X, Wu Y, Ni Y, Xu H, He Y. Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021. Front Public Health. 2025 Jan 23;13:1515797. doi: 10.3389/fpubh.2025.1515797. PMID: 39916706; PMCID: PMC11798972.
  66. Islam ANMS, Sultana H, Nazmul Hassan Refat M, Farhana Z, Abdulbasah Kamil A, Meshbahur Rahman M. The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: A meta-analysis. Prev Med Rep. 2024 Sep 5;46:102882. doi: 10.1016/j.pmedr.2024.102882. PMID: 39290257; PMCID: PMC11406007.
  67. Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. J Am Coll Cardiol. 2025 Dec 2;86(22):2167-2243. doi: 10.1016/j.jacc.2025.08.015. Epub 2025 Sep 24. PMID: 40990886.
  68. Rao GHR. Editorial: Insights in diabetes: molecular mechanisms 2022. Front Endocrinol (Lausanne). 2023 Aug 7;14:1242759. doi: 10.3389/fendo.2023.1242759. PMID: 37608793; PMCID: PMC10441663.
  69. Rao GHR. Cardiometabolic Diseases: A Global Perspective. J Cardiol & Cardiovasc Ther. 2018;12(2):ID555834.
  70. Tate A, Rao GHR.  Cardiometabolic Diseases: Cellular and Molecular Mechanisms. Cardiol Cardiovasc Res.2025;3(2):1-15.
  71. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003 Oct 28;108(17):2054-9. doi: 10.1161/01.CIR.0000089191.72957.ED. PMID: 14581384.
  72. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. doi: 10.1016/s0735-1097(01)01746-6. Erratum in: J Am Coll Cardiol 2002 Mar 20;39(6):1082. PMID: 11788217.
  73. Kasliwal RR, Bansal M, Mehrotra R, Yeptho KP, Trehan N. Effect of pistachio nut consumption on endothelial function and arterial stiffness. Nutrition. 2015 May;31(5):678-85. doi: 10.1016/j.nut.2014.10.019. Epub 2014 Nov 7. PMID: 25837212.
  74. Gerrard JM, Stuart MJ, Rao GH, Steffes MW, Mauer SM, Brown DM, White JG. Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J Lab Clin Med. 1980 Jun;95(6):950-8. PMID: 6445927.
  75. Takeda Y, Demura M, Yoneda T, Takeda Y. Epigenetic Regulation of the Renin-Angiotensin-Aldosterone System in Hypertension. Int J Mol Sci. 2024 Jul 25;25(15):8099. doi: 10.3390/ijms25158099. PMID: 39125667; PMCID: PMC11312206.
  76. Grossini E, Venkatesan S, Ola Pour MM. Mitochondrial Dysfunction in Endothelial Cells: A Key Driver of Organ Disorders and Aging. Antioxidants (Basel). 2025 Mar 21;14(4):372. doi: 10.3390/antiox14040372. PMID: 40298614; PMCID: PMC12024085.
  77. Zhan Y, Cao J, Ji L, Zhang M, Shen Q, Xu P, Zhuang X, Qin S, Hua F, Sun L, Li F, Chen H, Cheng Y. Impaired mitochondria of Tregs decreases OXPHOS-derived ATP in primary immune thrombocytopenia with positive plasma pathogens detected by metagenomic sequencing. Exp Hematol Oncol. 2022 Sep 1;11(1):48. doi: 10.1186/s40164-022-00304-y. PMID: 36050760; PMCID: PMC9434515.
  78. Janaszak-Jasiecka A, Płoska A, Wierońska JM, Dobrucki LW, Kalinowski L. Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets. Cell Mol Biol Lett. 2023 Mar 9;28(1):21. doi: 10.1186/s11658-023-00423-2. PMID: 36890458; PMCID: PMC9996905.
  79. Ma J, Li Y, Yang X, Liu K, Zhang X, Zuo X, Ye R, Wang Z, Shi R, Meng Q, Chen X. Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023 Apr 20;8(1):168. doi: 10.1038/s41392-023-01430-7. PMID: 37080965; PMCID: PMC10119183.
  80. Suzuki Y, Giles WR, Zamponi GW, Kondo R, Imaizumi Y, Yamamura H. Ca2+ signaling in vascular smooth muscle and endothelial cells in blood vessel remodeling: a review. Inflamm Regen. 2024 Dec 27;44(1):50. doi: 10.1186/s41232-024-00363-0. PMID: 39731196; PMCID: PMC11673324.
  81. Fajmut A. Molecular mechanisms and targets of cyclic guanosine monophosphate (cGMP) in vascular smooth muscles. [Internet].  In: Muscle Cell and Tissue-Novel molecular targets and advances. IntechOpen.2021Available from: http://doi.org/10.5772/intechopen.97708
  82. Rao GHR. Role of cyclic AMP and cyclic GMP as modulators of platelet cytosolic calcium. K Clin Prevent Cardiol.2016;5(3):99-103. doi:10.4103/2250-3528.191101.
  83. Ranadive SM, Dillon GA, Mascone SE, Alexander LM. Vascular Health Triad in Humans With Hypertension-Not the Usual Suspects. Front Physiol. 2021 Oct 1;12:746278. doi: 10.3389/fphys.2021.746278. PMID: 34658930; PMCID: PMC8517241.
  84. Rao GHR. Obesity is a unique metabolic disease. EC Clin and Med Case Rep. 2023; 6(8):01-11.
  85. Liu X, Zhang Z, Song Y, Xie H, Dong M. An update on brown adipose tissue and obesity intervention: Function, regulation and therapeutic implications. Front Endocrinol (Lausanne). 2023 Jan 11;13:1065263. doi: 10.3389/fendo.2022.1065263. PMID: 36714578; PMCID: PMC9874101.
  86. Taylor EB. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin Sci (Lond). 2021 Mar 26;135(6):731-752. doi: 10.1042/CS20200895. PMID: 33729498; PMCID: PMC7969664.
  87. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022 Jul 6;7(1):216. doi: 10.1038/s41392-022-01073-0. PMID: 35794109; PMCID: PMC9259665.
  88. Ragni M, Ruocco C, Nisoli E. Mitochondrial uncoupling, energy substrate utilization, and brown adipose tissue as therapeutic targets in cancer. NPJ Metab Health Dis. 2025 Sep 22;3(1):37. doi: 10.1038/s44324-025-00080-3. PMID: 40983641; PMCID: PMC12454651.
  89. Negroiu CE, Tudorașcu I, Bezna CM, Godeanu S, Diaconu M, Danoiu R, Danoiu S. Beyond the Cold: Activating Brown Adipose Tissue as an Approach to Combat Obesity. J Clin Med. 2024 Mar 28;13(7):1973. doi: 10.3390/jcm13071973. PMID: 38610736; PMCID: PMC11012454.
  90. Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R, Xu X, Li T. Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022 Aug 28;7(1):298. doi: 10.1038/s41392-022-01149-x. Erratum in: Signal Transduct Target Ther. 2022 Oct 21;7(1):369. doi: 10.1038/s41392-022-01188-4. PMID: 36031641; PMCID: PMC9420733.
  91. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23. Erratum in: Lancet. 2010 Mar 20;375(9719):984. PMID: 19853906.
  92. Liu J, Lang G, Shi J. Epigenetic Regulation of PDX-1 in Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2021 Feb 2;14:431-442. doi: 10.2147/DMSO.S291932. PMID: 33564250; PMCID: PMC7866918.
  93. Miura A, Yamagata K, Kakei M, Hatakeyama H, Takahashi N, Fukui K, Nammo T, Yoneda K, Inoue Y, Sladek FM, Magnuson MA, Kasai H, Miyagawa J, Gonzalez FJ, Shimomura I. Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. J Biol Chem. 2006 Feb 24;281(8):5246-57. doi: 10.1074/jbc.M507496200. Epub 2005 Dec 23. PMID: 16377800.
  94. Kaimala S, Kumar CA, Allouh MZ, Ansari SA, Emerald BS. Epigenetic modifications in pancreas development, diabetes, and therapeutics. Med Res Rev. 2022 May;42(3):1343-1371. doi: 10.1002/med.21878. Epub 2022 Jan 4. PMID: 34984701; PMCID: PMC9306699.
  95. Xiao Liang K. Interplay of mitochondria and diabetes: Unveiling novel therapeutic strategies. Mitochondrion. 2024 Mar;75:101850. doi: 10.1016/j.mito.2024.101850. Epub 2024 Feb 7. PMID: 38331015.
  96. Wang T, Wang J, Hu X, Huang XJ, Chen GX. Current understanding of glucose transporter 4 expression and functional mechanisms. World J Biol Chem. 2020 Nov 27;11(3):76-98. doi: 10.4331/wjbc.v11.i3.76. PMID: 33274014; PMCID: PMC7672939.
  97. Peng S, Li W, Hou N, Huang N. A Review of FoxO1-Regulated Metabolic Diseases and Related Drug Discoveries. Cells. 2020 Jan 10;9(1):184. doi: 10.3390/cells9010184. PMID: 31936903; PMCID: PMC7016779.
  98. Lee J, Salazar Hernández MA, Auen T, Mucka P, Lee J, Ozcan U. PGC-1α functions as a co-suppressor of XBP1s to regulate glucose metabolism. Mol Metab. 2018 Jan;7:119-131. doi: 10.1016/j.molmet.2017.10.010. Epub 2017 Oct 28. PMID: 29129613; PMCID: PMC5784318.
  99. Sanvictores T, Casale J, Huecker MR. Physiology, Fasting. 2023 Jul 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 30521298.
  100. Tsuchiya K, Ogawa Y. Forkhead box class O family member proteins: The biology and pathophysiological roles in diabetes. J Diabetes Investig. 2017 Nov;8(6):726-734. doi: 10.1111/jdi.12651. Epub 2017 Apr 19. PMID: 28267275; PMCID: PMC5668485.
  101. Solis-Herrera C, Triplitt C, Cersoimo E. DeFronzo RA: Pathogenesis of Type2 diabetes mellitus. In: Feingold KR Ahmed SF, Anawalt B et al;, editors. [Internet]. South Dartmouth (MA):MDtext.com Inc., 2000. https://www.ncbi.nlm.nih.gov/books/NBK279115.
  102. Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, Preckel B. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. J Clin Med. 2021 May 29;10(11):2419. doi: 10.3390/jcm10112419. PMID: 34072487; PMCID: PMC8199251.
  103. Vaidya AR, Wolska N, Vara D, Mailer RK, Schröder K, Pula G. Diabetes and Thrombosis: A Central Role for Vascular Oxidative Stress. Antioxidants (Basel). 2021 Apr 29;10(5):706. doi: 10.3390/antiox10050706. PMID: 33946846; PMCID: PMC8146432.
  104. Tian Y, Zong Y, Pang Y, Zheng Z, Ma Y, Zhang C, Gao J. Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduct Target Ther. 2025 May 16;10(1):159. doi: 10.1038/s41392-025-02198-8. PMID: 40374650; PMCID: PMC12081703.
  105. Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. J Intensive Care. 2015 Jan 7;3(1):2. doi: 10.1186/s40560-014-0066-z. PMID: 25705427; PMCID: PMC4336124.
  106. Houben AJHM, Stehouwer CDA. Microvascular dysfunction: Determinants and treatment, with a focus on hyperglycemia. Endocrine Met Sci 2:100073. https://doi.org/10.1016/j.endmts.2020.1000073.
  107. Taguchi K, Fukami K. RAGE signaling regulates the progression of diabetic complications. Front Pharmacol. 2023 Mar 16;14:1128872. doi: 10.3389/fphar.2023.1128872. PMID: 37007029; PMCID: PMC10060566.
  108. Chen Y, Meng Z, Li Y, Liu S, Hu P, Luo E. Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications. Mol Med. 2024 Sep 9;30(1):141. doi: 10.1186/s10020-024-00905-9. PMID: 39251935; PMCID: PMC11385660.
  109. Kant S, Feng J. Protein kinase C and endothelial dysfunction in select vascular diseases. Front Cardiovasc Med. 2025 Aug 25;12:1618343. doi: 10.3389/fcvm.2025.1618343. PMID: 40926896; PMCID: PMC12414950.
  110. Belhoul-Fakir H, Brown ML, Thompson PL, Hamzah J, Jansen S. Connecting the Dots: How Injury in the Arterial Wall Contributes to Atherosclerotic Disease. Clin Ther. 2023 Nov;45(11):1092-1098. doi: 10.1016/j.clinthera.2023.10.004. Epub 2023 Oct 25. PMID: 37891144.
  111. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, Benito-Vicente A, Martín C. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022 Mar 20;23(6):3346. doi: 10.3390/ijms23063346. PMID: 35328769; PMCID: PMC8954705.
  112. Feng Y, Li C, Liu B. Endothelial dysfunction in atherosclerosis: from classical pathways to emerging mechanisms. Vessel Plus. 2025; 9:8. Doi: 10.20517/2574-1209.2025.39 .
  113. Jiang H, Zhou Y, Nabavi SM, Sahebkar A, Little PJ, Xu S, Weng J, Ge J. Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis. Front Cardiovasc Med. 2022 Jun 1;9:925923. doi: 10.3389/fcvm.2022.925923. PMID: 35722128; PMCID: PMC9199460.
  114. Dash UC, Bhol NK, Swain SK, Samal RR, Nayak PK, Raina V, Panda SK, Kerry RG, Duttaroy AK, Jena AB. Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications. Acta Pharm Sin B. 2025 Jan;15(1):15-34. doi: 10.1016/j.apsb.2024.10.004. Epub 2024 Oct 16. PMID: 40041912; PMCID: PMC11873663.
  115. Chen R, McVey DG, Shen D, Huang X, Ye S. Phenotypic Switching of Vascular Smooth Muscle Cells in Atherosclerosis. J Am Heart Assoc. 2023 Oct 17;12(20):e031121. doi: 10.1161/JAHA.123.031121. Epub 2023 Oct 10. PMID: 37815057; PMCID: PMC10757534.
  116. Bonetti J, Corti A, Lerouge L, Pompella A, Gaucher C. Phenotypic Modulation of Macrophages and Vascular Smooth Muscle Cells in Atherosclerosis-Nitro-Redox Interconnections. Antioxidants (Basel). 2021 Mar 26;10(4):516. doi: 10.3390/antiox10040516. PMID: 33810295; PMCID: PMC8066740.
  117. Zapata-Martínez L, Águila S, de Los Reyes-García AM, Carrillo-Tornel S, Lozano ML, González-Conejero R, Martínez C. Inflammatory microRNAs in cardiovascular pathology: another brick in the wall. Front Immunol. 2023 May 18;14:1196104. doi: 10.3389/fimmu.2023.1196104. PMID: 37275892; PMCID: PMC10233054.
  118. Li C, Deng C, Shi B, Zhao R. Thin-cap fibroatheroma in acute coronary syndrome: Implication for intravascular imaging assessment. Int J Cardiol. 2024 Jun 15;405:131965. doi: 10.1016/j.ijcard.2024.131965. Epub 2024 Mar 15. PMID: 38492863.
  119. Baaten CCFMJ, Nagy M, Bergmeier W, Spronk HMH, van der Meijden PEJ. Platelet biology and function: plaque erosion vs. rupture. Eur Heart J. 2024 Jan 1;45(1):18-31. doi: 10.1093/eurheartj/ehad720. PMID: 37940193; PMCID: PMC10757869.
  120. Rao GHR. Cellular Signaling Pathways and Vascular Dysfunctions. J Cardiol Cardiovasc Ther.12 (4):55844, 2018.
  121. Rao GHR, Gerrard JM, Cohen I, Witkop CJ, White JG: Origin and role of calcium in platelet activation-contraction-secretion coupling. In: Fiskum, G (eds) Cell Calcium Metabolism. GWUMC Department of Biochemistry Annual Spring Symposia. Springer, Boston MA. https://doi.org/10.1007/978-1-4684-5598-4_44. ISBN 978-1-4684-5600-4. 1989.
  122. Rao GHR. Role of cyclic AMP and cyclic GMP as modulators of platelet cytosolic calcium J. Clin Prevent Cardiol. 2016; 5(3):99-103. doi:10.4103/2250-3528.191101.
  123. Higashi Y. Roles of Oxidative Stress and Inflammation in Vascular Endothelial Dysfunction-Related Disease. Antioxidants (Basel). 2022 Sep 30;11(10):1958. doi: 10.3390/antiox11101958. PMID: 36290681; PMCID: PMC9598825.
  124. Batty M, Bennett MR, Yu E. The Role of Oxidative Stress in Atherosclerosis. Cells. 2022 Nov 30;11(23):3843. doi: 10.3390/cells11233843. PMID: 36497101; PMCID: PMC9735601.
  125. Dilworth L, Facey A, Omoruyi F. Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. Int J Mol Sci. 2021 Jul 16;22(14):7644. doi: 10.3390/ijms22147644. PMID: 34299261; PMCID: PMC8305176.
  126. Han KH, Chang MK, Boullier A, Green SR, Li A, Glass CK, Quehenberger O. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest. 2000 Sep;106(6):793-802. doi: 10.1172/JCI10052. PMID: 10995790; PMCID: PMC381395.
  127. Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, Orekhov AN. Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis. Front Pharmacol. 2021 Jan 11;11:613780. doi: 10.3389/fphar.2020.613780. PMID: 33510639; PMCID: PMC7836017.
  128. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):15S-22S. doi: 10.1016/s0735-1097(02)02834-6. PMID: 12644336.
  129. Mahdinia E, Shokri N, Taheri AT, Asgharzadeh S, Elahimanesh M, Najafi M. Cellular crosstalk in atherosclerotic plaque microenvironment. Cell Commun Signal. 2023 May 30;21(1):125. doi: 10.1186/s12964-023-01153-w. PMID: 37254185; PMCID: PMC10227997.
  130. Rao GHR. Acute Vascular events: Cellular and Molecular Mechanisms. International Journal of Biomedicine. 2023;.13(3):9-16. doi:10.21103/Article13(3)_RA1.
  131. Tang S, An X, Sun W, Zhang Y, Yang C, Kang X, Sun Y, Jiang L, Zhao X, Gao Q, Ji H, Lian F. Parallelism and non-parallelism in diabetic nephropathy and diabetic retinopathy. Front Endocrinol (Lausanne). 2024 Feb 14;15:1336123. doi: 10.3389/fendo.2024.1336123. PMID: 38419958; PMCID: PMC10899692.
  132. Manful CF, Fordjour E, Ikumoinein E, Abbey L, Thomas R: Therapeutic strategies targeting Oxidative stress and inflammation: A narrative review. Biochem 5(4):35, 2025. https://doi.org/10.3390/biochem5040035
  133. Xue J, Zhang Z, Sun Y, Jin D, Guo L, Li X, Zhao D, Feng X, Qi W, Zhu H. Research Progress and Molecular Mechanisms of Endothelial Cells Inflammation in Vascular-Related Diseases. J Inflamm Res. 2023 Aug 23;16:3593-3617. doi: 10.2147/JIR.S418166. PMID: 37641702; PMCID: PMC10460614.
  134. Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, McGhie DV, Mwangi J, Pervan B, Narula J, Pineiro D, Pinto FJ. The Heart of the World. Glob Heart. 2024 Jan 25;19(1):11. doi: 10.5334/gh.1288. PMID: 38273998; PMCID: PMC10809869.
  135. Abohelwa M, Kopel J, Shurmur S, Ansari M, Awasthi Y, Awasthi S. The Framingham study of cardiovascular disease risks and stress -defenses: A Historical Review. J Vasc Dis. 2023;2(1):122-164.
  136. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937-52. doi: 10.1016/S0140-6736(04)17018-9. PMID: 15364185.
  137. Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, Fuster V, Boerwinkle E, Melander O, Orho-Melander M, Ridker PM, Kathiresan S. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016 Dec 15;375(24):2349-2358. doi: 10.1056/NEJMoa1605086. Epub 2016 Nov 13. PMID: 27959714; PMCID: PMC5338864.
  138. Rao GHR, Kakkar VJ. Coronary artery disease in South Asians. Epidemiology, Risk Factors and Prevention. Jaypee Medical Publishers, India. 2001 ISBN# 81-7179-811-X.
  139. Attia P, Gifford B. Outlive: The science and art of longevity. 2023. First Edition, Harmony, New York.
  140. Tate AR, Rao GHR. Inflammation: Is It a Healer, Confounder, or a Promoter of Cardiometabolic Risks? Biomolecules. 2024 Aug 6;14(8):948. doi: 10.3390/biom14080948. PMID: 39199336; PMCID: PMC11352362.

Download Article
Received March 9, 2026.
Accepted March 23, 2026.
© 2026 The Author(s). International Journal of Biomedicine is published by IMRDC. This is an open access article under the CC BY-NC-ND 4.0 license.